VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Stopped early · Phase 1/Phase 2

Conditions studied: Low Grade B Cell Lymphoma

In brief

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Key facts

Study ID

NCT01289210

Run by

Celgene

People needed

2

Starts

2011-07-01

Expected to finish

2012-10-01

Last updated by the study team

2019-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Known HIV
• Known brain metastases
• Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
• Anticoagulation therapy other than 325mg QD ASA
• Significant cardiovascular disease
• Pregnant or nursing

Where it is running

• Stanford Cancer Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.